<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699721</url>
  </required_header>
  <id_info>
    <org_study_id>202007093</org_study_id>
    <nct_id>NCT04699721</nct_id>
  </id_info>
  <brief_title>Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC</brief_title>
  <official_title>Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with&#xD;
      probiotics for early resectable NSCLC patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse effects</measure>
    <time_frame>90 days after the first medication or 30 days after the operation, whichever is later</time_frame>
    <description>safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical complications (intra-operative and peri-operative)</measure>
    <time_frame>90 days after the first medication or 30 days after the operation, whichever is later</time_frame>
    <description>safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>non-R0 surgical events</measure>
    <time_frame>28 days after the completion of three cycles of neoadjuvant therapy</time_frame>
    <description>effectiveness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>12 weeks (±7 days) after the operation, then every 12 weeks for 2 years</time_frame>
    <description>effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Pathologic Response</measure>
    <time_frame>12 weeks (±7 days) after the operation, then every 12 weeks for 2 years</time_frame>
    <description>effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>1 year and 2 years after the operation</time_frame>
    <description>effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>1 year and 2 years after the operation</time_frame>
    <description>effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time from beginning of treatment to death or 2 year, whichever comes first</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-small Cell Lung Cancer Stage III</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5</intervention_name>
    <description>3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)</description>
    <other_name>Bifidobacterium trifidum live powder (BiFico, SINE)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed previously untreated non-small cell lung&#xD;
             cancer. Patients with stage IIIA and potentially resectable stage IIIB (T3N2) disease&#xD;
             (according to AJCC 8th edition) are eligible ;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score 0-1;&#xD;
&#xD;
          -  18 years ≤ Age ≤ 80 years. Signed and dated written informed consent must be provided&#xD;
             by the patient prior to admission to the study;&#xD;
&#xD;
          -  Patients with appropriate treatment compliance and could be followed-up correctly;&#xD;
&#xD;
          -  Measurable or evaluable diseases (according to RECIST 1.1);&#xD;
&#xD;
          -  Patients must have the ability to swallow oral drugs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll;&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration. Inhaled or topical steroids and adrenal replacement&#xD;
             doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             autoimmune disease;&#xD;
&#xD;
          -  Patients with symptomatic ILD (grade 3-4) and/or poor lung function and a history of&#xD;
             interstitial lung disease cannot be included. If you have any questions, please&#xD;
             contact the trial team;&#xD;
&#xD;
          -  Patients with other active malignant tumors currently receiving cancer therapy&#xD;
             (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or&#xD;
             investigational anti-cancer drug;&#xD;
&#xD;
          -  Patients who are inability to follow the procedures required in the protocol due to&#xD;
             any medical, mental or psychological conditions;&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody or any other&#xD;
             antibodies or drugs that target T cell costimulation or immune checkpoint pathways;&#xD;
&#xD;
          -  Known positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C&#xD;
             virus ribonucleic acid indicating acute or chronic infection;&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus or known acquired&#xD;
             immunodeficiency syndrome;&#xD;
&#xD;
          -  Patients with a history of allergy to study drugs or ingredients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Gao, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Gao, Doctor</last_name>
    <phone>+86 13973171096</phone>
    <email>drgaoyang@sina.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhaoqian Liu, Doctor</last_name>
    <phone>+86 13787797720</phone>
    <email>zqliu@csu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Gao, Doctor</last_name>
      <phone>+86 13973171096</phone>
      <email>drgaoyang@sina.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhaoqian Liu, Doctor</last_name>
      <phone>+86 13787797720</phone>
      <email>zqliu@csu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>IPD will be shared when the clinical trail is finished</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

